Last updated: March 13, 2026
What is NDC 69680-0165?
NDC 69680-0165 is the identifier for a specific pharmaceutical product. Based on available databases, this NDC corresponds to Rybelsus (semaglutide), a GLP-1 receptor agonist used in the treatment of type 2 diabetes.
Market Overview
Product Use and Approval
- Indication: Type 2 diabetes mellitus
- FDA Approval: September 2019
- Administration: Oral tablet (14 mg dosage)
- Market Launch: Q4 2019
Market Size
- The global diabetes drugs market was valued at approximately $76 billion in 2021.
- The U.S. accounted for nearly 45% of this market.
- The oral GLP-1 receptor agonists segment, led by Rybelsus, showed rapid growth since 2019.
Market Drivers
- Rising prevalence of type 2 diabetes, projected to increase globally from 537 million in 2021 to 643 million by 2030.
- Preference for oral medications over injectable therapies.
- Efficacy demonstrated in cardiovascular outcome trials.
- Competitive entry by other GLP-1 agents (e.g., Trulicity, Ozempic).
Competition Landscape
| Product |
Formulation |
Market Share (2022)* |
Approval Year |
Key Features |
| Rybelsus |
Oral tablet |
25% |
2019 |
First oral GLP-1 receptor agonist |
| Ozempic |
Injectable |
45% |
2017 |
Once-weekly dosing |
| Trulicity |
Injectable |
20% |
2014 |
Weekly dosing |
| Other |
Various |
10% |
- |
Combines new mechanisms |
*Market share percentages approximate based on IQVIA data.
Price Analysis
Current Wholesale Acquisition Cost (WAC)
- Rybelsus (14 mg, 30 tablets): approximately $850–$900 per month.
- This price has remained relatively stable since approval, barring minor adjustments.
Rebates and Net Price
- Manufacturer rebates and discounts reduce the net price to $660–$750.
- Variability depends on payor contracts, geographic region, and pharmacy benefit managers.
Price Comparators
| Drug |
Formulation |
Monthly WAC |
Annual Cost |
Notes |
| Rybelsus (14 mg) |
Oral tablet |
$850–$900 |
$10,200–$10,800 |
First oral GLP-1 |
| Ozempic (0.5 mg) |
Injectable |
$800–$850 |
$9,600–$10,200 |
Weekly injection |
| Trulicity (0.75 mg) |
Injectable |
$850–$900 |
$10,200–$10,800 |
Weekly injection |
Price Trends and Forecasts
Price projections consider several factors:
- Market penetration: Continued adoption as first-line oral therapy.
- Patent and exclusivity: Patent protections extend to 2029–2030, delaying generic competition.
- Pricing pressures: Increased competition and biosimilar development could lower prices by 5-10% over five years.
- Rebate trends: Growing emphasis on rebates and value-based pricing could further reduce net prices by $50–$150 annually.
Projected annual net prices for Rybelsus are anticipated to decline gradually from $660 to $600–$650 by 2028, assuming competitive pressures and cost containment policies.
Regulatory and Market Forces Impacting Price
- Patent expirations: No immediate generic availability expected before 2029.
- Biosimilars: Development efforts for semaglutide biosimilars are underway but face regulatory and manufacturing hurdles.
- Reimbursement policies: CMS and private insurers are increasingly favoring cost-effective therapies, potentially limiting reimbursement rates.
- Pricing policies: Negotiations and legislation targeting drug prices may influence net prices.
Key Takeaways
- NDC 69680-0165, likely Rybelsus, holds a significant share in the oral diabetes medication market.
- The current wholesale list price is around $850–$900 monthly, with net prices lower due to rebates.
- Market growth is driven by increasing diabetes prevalence and patient preference for oral therapies.
- Price declines of 5–10% over the next five years are probable, influenced by competition and policy changes.
- Patent protection shields cost reductions from biosimilar entries until 2029.
FAQs
1. What factors could accelerate price declines for Rybelsus?
Introduction of biosimilars, increased generic competition, and policy measures targeting drug pricing could lower prices faster.
2. How does Rybelsus compare to injectable GLP-1 therapies in pricing?
Oral Rybelsus generally has a higher monthly list price than weekly injectables; however, patient preference and adherence influence actual costs and market share.
3. What is the outlook for market share for Rybelsus?
Market share growth depends on prescriber acceptance, patient adherence, and competitive dynamics. It could surpass 30% within the next three years if adoption continues.
4. Will the pricing trend impact access or affordability?
Yes; as net prices decline, payers may expand access, but high list prices and rebates can influence out-of-pocket costs.
5. Are there upcoming regulatory changes that could influence pricing?
Potential legislation targeting drug prices, increased transparency, and biosimilar pathways could impact future pricing strategies.
Sources
- IQVIA. (2022). Pharmaceutical Market Data.
- FDA. (2019). Rybelsus (semaglutide) Prescribing Information.
- EvaluatePharma. (2022). Global Diabetes Drugs Market Outlook.
- U.S. Department of Health and Human Services. (2022). Rebate and pricing policies.
- PharmacoEconomics. (2021). Impact of biosimilars on Drug Pricing.
